Sasahira, Naoki

Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study

Lee, M. S., Ryoo, B.-Y., Hsu, C.-H., Numata, K., Stein, S., Verret, W., Hack, S. P., Spahn, J., Liu, B., Abdullah, H., et al. (2020) · The Lancet Oncology

Hepatocellular Carcinoma Treatment and PrognosisCancer Immunotherapy and Biomarkers

Cited by 562

Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma

Sangro, B., Chan, S. L., Kelley, R. K., Lau, G., Kudo, M., Sukeepaisarnjaroen, W., Yarchoan, M., De Toni, E. N., Furuse, J., Kang, Y. K., et al. (2024) · Annals of Oncology

Hepatocellular Carcinoma Treatment and PrognosisCancer Immunotherapy and Biomarkers

Cited by 365

Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial

Nakachi, K., Ikeda, M., Konishi, M., Nomura, S., Katayama, H., Kataoka, T., Todaka, A., Yanagimoto, H., Morinaga, S., Kobayashi, S., et al. (2023) · The Lancet

Cholangiocarcinoma and Gallbladder Cancer StudiesGallbladder and Bile Duct Disorders

Cited by 258

Prediction model for pancreatic cancer risk in the general Japanese population

Nakatochi, M., Lin, Y., Ito, H., Hara, K., Kinoshita, F., Kobayashi, Y., Ishii, H., Ozaka, M., Sasaki, T., Sasahira, N., et al. (2018) · PLOS ONE

Pancreatic and Hepatic Oncology ResearchGenetic Associations and Epidemiology

Cited by 45

Post‐operative mortality and recurrence patterns in pancreatic cancer according to KRAS mutation and CDKN2A , p53, and SMAD4 expression

Masugi, Y., Takamatsu, M., Tanaka, M., Hara, K., Inoue, Y., Hamada, T., Suzuki, T., Arita, J., Hirose, Y., Kawaguchi, Y., et al. (2023) · The Journal of Pathology: Clinical Research

Pancreatic and Hepatic Oncology ResearchCancer Genomics and Diagnostics

Cited by 23